#ACC21 – [Ainda não publicado] Estudo randomizado – DARE-19: Dapaglifozina é segura, mas não melhora significativamente o desfecho entre pacientes de alto risco hospitalizados com COVID-19.

DARE-19: Dapagliflozin in High-Risk Patients Hospitalized With COVID-19 – American College of Cardiology

Ver também: Dapagliflozin in Respiratory Failure in Patients With COVID-19 – DARE-19 – American College of Cardiology

Comentários no Twitter

DARE-19 trial #ACC21 @ACCinTouch

Dapa did not reduce clinical endpoints in #COVID19, but excellent safety profile

🎯 Do not discontinue SGLT2i in 🏥 for #COVID19

Full slideset available in 👇https://t.co/RPi5mpPbbN pic.twitter.com/B9VQdSSAFu

— Enrique Santas (@SantasEnrique) May 16, 2021

DARE-19 findings presented at #ACC21 show #dapagliflozin didn’t significantly ⬇️ risk of organ failure or death or improve recovery in patients hospitalized w/ #COVID19. However, data suggest the SGLT2 inhibitor was well tolerated in acutely ill patients. https://t.co/YjYxbuc952 pic.twitter.com/J4PqwvGpLJ

— American College of Cardiology (@ACCinTouch) May 16, 2021